AI Model Predicts Breast Cancer Recurrence from Pathology Slides

Agendia has validated an AI model that predicts breast cancer recurrence risk from routine pathology slides with high accuracy, matching results of a 70-gene genomic test in a study of 372 patients with over 10 years follow-up. The AI classification independently predicts survival better than standard clinical factors and could expand access to genomic risk assessment globally where genomic testing is limited.

This Wire brief sits within Fusion42's coverage of Biotech, Diagnostics and AI Frontier Models.